Evaxion Biotech re-established compliance with Nasdaq

Evaxion Biotech (EVAX) has received confirmation from the Nasdaq Stock Market that it has re-established compliance with Nasdaq’s minimum stockholders’ equity requirement. Nasdaq has withdrawn its determination to delist Evaxion, and the company will remain listed as fully compliant with Nasdaq’s rules. “We are very pleased to have received formal confirmation that we are again fully compliant with Nasdaq’s rules and will remain listed as we always planned for. We thank Nasdaq for a constructive dialogue on the matter. Having significantly strengthened our equity and cash position, full focus is now on executing upon our strategy and pursuing our 2025 milestones”, says Christian Kanstrup, CEO of Evaxion.